- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- Fludarabine, Obinutuzumab, Bendamustine, Cyclophosphamide
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 18
- States / cities
- Huntsville, Alabama • Duarte, California • La Jolla, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 865–888
of 11,406
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Macular Edema
- Interventions
- 2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab
- Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 90
- States / cities
- Tucson, Arizona • Beverly Hills, California • Loma Linda, California + 72 more
- Conditions
- Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts, RAEB
- Interventions
- rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC)
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 81 Years
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 32
- States / cities
- La Jolla, California • Los Angeles, California • Fleming Island, Florida + 25 more
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts, Secondary Acute Myeloid Leukemia
- Interventions
- Pretargeted Radioimmunotherapy, Cyclosporine, Mycophenolate Mofetil, Total-Body Irradiation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Fludarabine Phosphate, Pharmacological Study, Laboratory Biomarker Analysis
- Biological · Drug · Radiation + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Graft-versus-host Disease
- Interventions
- Itacitinib, Placebo, Methylprednisolone, Prednisone
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 39
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more
- Conditions
- Healthy Volunteers
- Interventions
- Vortioxetine, Paroxetine, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 361 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 15
- States / cities
- Encino, California • Long Beach, California • Torrance, California + 12 more
- Conditions
- Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
- Interventions
- Emricasan, Placebo
- Drug
- Lead sponsor
- Histogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 22
- States / cities
- Pasadena, California • Rialto, California • Palmetto Bay, Florida + 16 more
- Conditions
- Breast Cancer
- Interventions
- Electronic brachytherapy (Axxent System)
- Radiation
- Lead sponsor
- Xoft, Inc.
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 10
- States / cities
- San Mateo, California • Marietta, Georgia • Chicago, Illinois + 7 more
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, therapeutic tumor infiltrating lymphocytes
- Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
- Interventions
- Deramiocel (CAP-1002), Placebo
- Biological
- Lead sponsor
- Capricor Inc.
- Industry
- Eligibility
- 10 Years and older · Male only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 17 more
- Conditions
- Bradycardia, Sinus Node Dysfunction
- Interventions
- MRI, ImageReady System implant
- Radiation · Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 29
- States / cities
- Mesa, Arizona • Los Angeles, California • San Francisco, California + 26 more
- Conditions
- HIV Infections
- Interventions
- Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1995
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • San Francisco, California • San Jose, California + 11 more
- Conditions
- Heart Valve Disease
- Interventions
- On-X valve using reduced anticoagulation, On-X Valve with Standard warfarin Therapy
- Device
- Lead sponsor
- On-X Life Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 977 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2023
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Loma Linda, California • Hartford, Connecticut + 34 more
- Conditions
- HIV Infections, HIV Wasting Syndrome
- Interventions
- Optimune oral nutritional supplement
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 18
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 12 more
- Conditions
- Conventional Chondrosarcoma
- Interventions
- IPI-926, Placebo Arm
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Aurora, Colorado + 11 more
- Conditions
- Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
- Interventions
- Nivolumab, Everolimus
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 821 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 39
- States / cities
- Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 29 more
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- nonmyeloablative allogeneic hematopoietic stem cell transplantation, donor lymphocytes, cyclosporine, total-body irradiation, fludarabine phosphate, mycophenolate mofetil, laboratory biomarker analysis, peripheral blood stem cell transplantation
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 3
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Omacetaxine mepesuccinate
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Beech Grove, Indiana • Baltimore, Maryland + 5 more
- Conditions
- Sexual Behavior, Alcohol Drinking, Condomless Sex
- Interventions
- Online program
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 24 Years · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 61
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Bellflower, California + 55 more
- Conditions
- Neoplasm Metastasis, Non-Small Cell Lung Cancer
- Interventions
- zongertinib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Duarte, California + 17 more
- Conditions
- Breast Carcinoma, Cancer Survivor, Depression, Fatigue, Leukemia, Lymphoma, Malignant Bone Neoplasm, Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Pain, Sleep Disorder, Soft Tissue Sarcoma
- Interventions
- Management of Therapy Complications, Quality-of-Life Assessment, Questionnaire Administration, Telephone-Based Intervention
- Procedure · Other · Behavioral
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
- Interventions
- therapeutic autologous lymphocytes, cyclophosphamide, aldesleukin, polymerase chain reaction, gene rearrangement analysis, lymph node biopsy, genetically engineered lymphocyte therapy, bone marrow aspiration, flow cytometry, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Ketosis
- Interventions
- LEVL (Medamonitor)
- Device
- Lead sponsor
- Medamonitor
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 61 participants
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Seattle, Washington